- Home
- SLN vs EVCM Comparison
SLN vs EVCM Comparison
Compare SLN & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLN | EVCM |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLN | EVCM |
|---|---|---|
| Price | $19.76 | $8.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $19.75 | $8.25 |
| AVG Volume (30 Days) | ★ 4.4M | 76.0K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 145.45 |
| EPS | N/A | ★ 0.13 |
| Revenue | $559,000.00 | ★ $588,907,000.00 |
| Revenue This Year | N/A | $1.89 |
| Revenue Next Year | $131.31 | $2.74 |
| P/E Ratio | ★ N/A | $63.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $6.01 |
| 52 Week High | $19.87 | $14.41 |
Technical Indicators
Market Signals| Indicator | SLN | EVCM |
|---|---|---|
| Relative Strength Index (RSI) | 78.21 | 37.37 |
| Support Level | $13.01 | $7.46 |
| Resistance Level | $19.87 | $10.05 |
| Average True Range (ATR) | 0.07 | 0.57 |
| MACD | -0.04 | -0.15 |
| Stochastic Oscillator | 58.49 | 55.50 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.